AIImpactLab
9 impact clustersWork & marketsCognition & learningTechnical failuresPrivacySecurityEnvironmentLaw & informationSocial good & healthSystemic risk
Search the evidence

Find the signal.

Search titles, impact clusters, countries, organizations and the full text of every analysis.

9 stories found

Layers of translucent teal and blue paper form a brain above a slide speckled with violet marks. This is a concept illustration, not a patient scan.
Social good & healthInternational research cohorts+1 clusters01

Which children could safely get less radiation? A tumor test offers a clue

A family dealing with a childhood brain tumor faces two different futures at once. Parents want the treatment most likely to keep the cancer from coming back. They also want to protect the child who will have to live with what that treatment does to memory and learning. A new Nature Genetics study offers a way to ask more precisely which children might benefit from less radiation. The researchers built MANTIS using tumor DNA methylation profiles from 2,786 patients across two diseases, medulloblastoma and ependymoma. Methylation marks are chemical tags on DNA; many centers already use the patterns to help classify brain tumors. MANTIS uses those data to estimate an individual survival curve over ten years. The medulloblastoma model was validated in three separate clinical-trial cohorts totaling 898 patients. That is a test against real follow-up data, not a trial in which a model chose a child’s treatment. The team then revisited radiation doses for average-risk medulloblastoma. Its analysis singled out roughly 60% of the patients studied in that setting as possible candidates for lower-dose radiation to the brain and spine. The researchers did not detect a statistically significant survival disadvantage in that selected group; lower doses were associated with better cognitive outcomes. A difference too small to detect in one analysis can still matter enormously to a child. The promising result is a testable way to select patients for a trial, not evidence that six in ten children receiving cancer care should have treatment reduced.

4 min
A hand selects a lens beside a notebook, representing clinical checking and independent understanding.
Social good & healthGlobal+2 clusters02

A better AI answer can still need a better human check.

There is something genuinely encouraging in the new clinical reasoning study: the human check was not merely ceremonial. It helped improve the result. There is also a warning against judging a system by the right answers alone. The Nature Communications paper compares six matched pairs of reasoning and standard language models on retrospective clinical records. Reasoning models were better at including the primary diagnosis, but they also suggested more false-positive diagnoses. A separate validation exercise with fifteen physicians found benefits from structured collaboration. These are controlled retrospective findings, not proof of improved outcomes for patients in routine care. That distinction changes the design question. A longer list of plausible diagnoses can help a clinician consider something overlooked. It can also create unnecessary work if the extra possibilities are treated as conclusions. The quality of the workflow depends on how suggestions are challenged, not just how many the model can produce. The second paper, in Communications Psychology, addresses a related but different problem. Its SYNC framework separates performance with AI assistance from durable human learning. It is a Perspective proposing mechanisms and practices, not a new trial proving that a particular intervention works. I read the two together as an invitation to ask three questions. Did assistance improve the task? Were the additional errors caught? Can the person still explain and apply the reasoning without the tool later? The clinical paper offers evidence relevant to the first two. The learning framework gives a vocabulary for investigating the third. That is an editorial comparison, not a claim that one study validates the other. We can welcome useful assistance while refusing to let a polished answer stand in for either safety or understanding.

4 min
A researcher examines imaging slices with warm brown-fat signals while a separate mouse study remains in the background.
Social good & healthUnited States+2 clusters03

AI helped map brown fat in thousands of scans. The drug clue is not a cure.

An existing blood-pressure medicine has become an intriguing candidate in brown-fat research, but the evidence has not crossed into a human treatment claim. In a peer-reviewed Nature study, researchers analyzed imaging and records from 101,243 patients at a large cancer center. Brown fat, which spends energy producing heat, was associated with lower prevalence of several cardiovascular and psychiatric diagnoses. Machine learning allowed the team to semi-automatically quantify brown-fat activity in roughly 8,700 patients. Higher activity, particularly in one underarm depot, correlated with lower odds of cardiometabolic disease and a healthier distribution of white fat. Medication records then pointed to a class of blood-pressure drugs. Follow-up tests found that losartan increased brown-fat cell activity and energy expenditure in mice. That sequence matters: the AI analysis helped move from a broad clinical pattern to a specific, experimentally testable mechanism. It also sets a firm boundary. These patients were not randomized to change brown-fat activity; they were drawn from a cancer center; and the losartan result was not a trial showing improved human outcomes. The NIH describes it as a possible route to future drug repurposing, not a current indication. Patients should not alter medication because of a headline. The next evidence should be replication in other populations and prospective testing that measures patient outcomes, dosage and adverse effects. The real success of AI here is accelerating a scientific question without pretending the answer is finished.

6 min
An unfinished mathematics notebook sits beside the glow of an AI answer on a screen.
Cognition & learningGlobal+2 clusters04

AI help raised short-term scores, then weakened independent performance

The unnerving part of this study is not that AI gave wrong answers. It often helped people solve the immediate problem. The cost appeared after the tool was removed. In randomized experiments involving 1,222 participants, researchers tested fraction problems and reading comprehension. Across the experiments, assisted performance improved, but later unaided performance fell. Participants also skipped more problems in some conditions. The pattern appeared after roughly ten to fifteen minutes of use. That is an experimental result about short tasks, not evidence that any individual's intelligence has permanently declined. One replication found a smaller accuracy gap, and its overall skip-rate difference was not statistically significant. A subgroup analysis suggested the largest persistence cost among people who sought direct answers, but that comparison was observational within the trial and should not be called causal. The practical implication is a design choice: an assistant that always finishes the problem may optimize the visible score while removing the practice that builds competence. Teachers and employers should test what people can do without the tool, not merely count AI-assisted output. Developers could compare answer-giving against hint-first or delayed-help designs. The paper began as an April preprint and was revised October 3; it is not a new experiment performed today.

5 min
A patient reviews clear AI-prepared questions before meeting a surgeon, with an anxiety gauge and consultation timer both falling.
Social good & healthChina+4 clusters05

A local AI briefing cut pre-surgery anxiety and physician workload

A randomized phase II study offers a bounded example of medical AI that helped without pretending to replace the clinician. Researchers assigned 268 people newly diagnosed with prostate cancer and scheduled for radical prostatectomy to standard communication or an AI-assisted pathway. The intervention used a locally deployed large language model to prepare personalized answers to patient questions before the routine face-to-face discussion. Physicians remained responsible for the encounter and were blinded to group assignment. The AI-assisted group reported a mean post-communication GAD-7 anxiety score of 3.2, compared with 5.7 in the control group. Physician workload on the NASA-TLX scale averaged 39.9 versus 56.8, and routine communication time fell from 19.9 to 11.3 minutes. Satisfaction, emotions, and illness perceptions also improved. This is stronger evidence than a product testimonial, but it is not a general verdict on AI in medicine. The study was conducted at one cancer center, used a specific preoperative setting, measured near-term outcomes, and does not establish diagnostic accuracy, surgical outcomes, or long-term safety. The trial registry also still shows an earlier estimated enrollment of 160 and future completion dates, while the published paper reports 268 randomized participants; that record mismatch should be clarified. The design’s most important feature is the boundary: the model answered common questions in advance, responses were reviewed, and the surgeon still conducted the consent conversation. AI did not replace the relationship. It gave the relationship a better starting point.

10 min
An ordinary chest CT reveals a small illuminated esophageal lesion while an AI triage path directs the patient toward confirmatory endoscopy.
Social good & healthChina and international validation sites+4 clusters06

AI found hidden esophageal cancers in CT scans patients already had

A multicenter Nature Medicine study reports that an AI system called EAGLE can identify esophageal cancer and precancerous lesions in noncontrast chest CT scans that were not acquired specifically for the esophagus. The model was trained on 6,813 patients and validated across 12 centers in three countries involving 80,612 patients. In external cohorts totaling 11,466 people, it reached 90.0 percent sensitivity for cancer and 98.5 percent specificity, while sensitivity for precancerous lesions was lower at 52.5 percent. A calibration cohort of 35,402 patients reduced false positives by 72.7 percent while preserving sensitivity. In a prospective hospital cohort of 17,446 patients, 38 of 90 positive predictions were true positives, producing a 42.2 percent positive predictive value and 87.8 percent sensitivity for cancer. A real-world low-dose screening cohort of 10,959 people reported 99.94 percent specificity. The opportunity is unusually practical: use scans already being performed to identify people who should receive confirmatory endoscopy. But the strongest efficiency claims remain modeled. Simulations suggested triage could triple detection, reduce diagnostic time by 70.4 percent, and lower costs in seven of eight countries. Those are not randomized outcomes or evidence of reduced mortality. Most data came from China, follow-up was under two years, endoscopy adherence was limited, and broader validation is needed for different disease patterns. EAGLE may make existing imaging more valuable. It has not yet proved that population deployment improves survival or avoids harmful overdiagnosis.

10 min
A bright conversational knowledge pathway rises beside a closed clinical decision gate that remains in the same position.
Social good & healthJapan+3 clusters07

An HPV chatbot improved vaccine literacy without changing vaccination decisions

A randomized clinical trial in Japan found that an AI chatbot modestly improved HPV vaccine literacy compared with a standard government leaflet, but it did not measurably change caregivers' vaccination decisions after two weeks. The trial randomized 848 female caregivers of unvaccinated daughters aged 12 to 18. Its modified intention-to-treat analysis included 704 participants immediately and 477 at the two-week literacy follow-up. After adjustment, the chatbot group scored 0.30 points higher on a seven-point literacy scale at both time points. The decision result was different: 40.3 percent of assessed caregivers in the chatbot group and 39.6 percent in the leaflet group met the study's decision-to-vaccinate definition, with no statistically significant difference. The chatbot used GPT-4o with a Japan-specific library drawn from official and peer-reviewed material, stayed within a defined scope, and directed personal clinical questions to professionals. This is useful causal evidence for a narrow intervention, not proof that general-purpose chatbots improve health behavior. Attrition was substantial, participants were all female caregivers recruited online, most had college or university education, and follow-up was short. The clearest lesson is not that the chatbot failed. It is that knowledge and action are different outcomes. Scalable conversation may strengthen literacy, while trust, clinician relationships, access, and social context still determine what people do.

9 min
A transparent lung scan and clinical evidence panel pass through several hospital environments while a performance signal changes between sites.
Social good & healthEurope+2 clusters08

Explainable AI improved oncologists’ lung-cancer predictions, but external validation exposed the limits

A multi-country study in Nature Medicine evaluated explainable AI support for treatment decisions in advanced non-small-cell lung cancer. The retrospective I3LUNG cohort included 2,396 patients treated with immunotherapy-based regimens across six centers in six countries. Models using routine clinical and blood data achieved test performance up to an area under the curve of 0.77 and outperformed traditional single biomarkers and clinical scores in the independent test set. In a separate usability study, twenty oncologists reviewed one hundred cases first without and then with model predictions and SHAP-based explanations. Sensitivity for predicting disease control increased from 0.72 to 0.87, with gains in accuracy and F1 performance; overall-survival prediction improved more modestly. The paper is valuable because it reports the limits alongside the gains. External-validation performance fell to an AUC range of 0.55 to 0.72, the complete multimodal sample was small, and added imaging, pathology, and genomic data did not produce a reliable benefit across test and external cohorts. Differences between patient populations may explain some decline, which is exactly why local calibration and prospective evaluation matter. The authors describe silent prospective validation in more than two thousand patients, another usability study, and a planned pragmatic randomized trial before deployment. The result is promising decision support, not autonomous clinical authority.

7 min
A bright AI tutor screen waits in a quiet classroom while empty login indicators and unused student desks dominate the evidence board.
Cognition & learningUnited States+2 clusters09

Nearly half of students never used the AI tutor assigned to them

Futurism highlights a pair of randomized school trials that tested whether human support could increase use of an AI literacy tutor. The primary working paper covers 355 elementary students across two districts. Despite dedicated time, only 60.7 percent and 53.3 percent of students assigned to use the platform independently ever used it; average weekly use was 2.18 and 5.23 minutes. Human tutors focused on motivation, accountability, reflection, and troubleshooting rather than direct reading instruction. Their presence increased use by about one minute a week in one district and 4.4 minutes in the other, while engagement measured by stories completed rose 71 to 80 percent relative to the control averages. The percentage gains sound large because the baseline was extremely low. Usage remained well below the platform provider's recommended 30 minutes a week, and the intervention did not improve reading achievement. The researchers do not conclude that AI tutoring is ineffective because the students never received enough exposure to test that claim. The result is still a warning for procurement: access, scheduled time, and a capable product are not implementation. Schools should require evidence of sustained use, learning outcomes, equitable participation, and the human support costs needed to make the tool matter.

6 min